{"pmid":32459003,"title":"A Role for Retinoids in The Treatment of Covid-19?","text":["A Role for Retinoids in The Treatment of Covid-19?","The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or Covid-19) is a serious threat to international health and thus there is an urgent need for discovery of novel therapies or use of repurposed drugs that can make a significant impact on slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of the early innate immune response to viruses that are being tested against SARS-CoV-2. However coronaviruses similar to SARS-CoV-2 can suppress host IFN-I anti-viral responses. Retinoids are a family molecules related to vitamin A that possess robust immune modulating properties, including the ability to increase and potentiate the actions of IFN-I. Therefore adjuvants such as retinoids, capable of increasing IFN-I mediated anti-viral responses should be tested in combinations of IFN-I and anti-viral drugs in pre-clinical studies of SARS-CoV-2.","Clin Exp Pharmacol Physiol","Trasino, Steven E","32459003"],"abstract":["The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or Covid-19) is a serious threat to international health and thus there is an urgent need for discovery of novel therapies or use of repurposed drugs that can make a significant impact on slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of the early innate immune response to viruses that are being tested against SARS-CoV-2. However coronaviruses similar to SARS-CoV-2 can suppress host IFN-I anti-viral responses. Retinoids are a family molecules related to vitamin A that possess robust immune modulating properties, including the ability to increase and potentiate the actions of IFN-I. Therefore adjuvants such as retinoids, capable of increasing IFN-I mediated anti-viral responses should be tested in combinations of IFN-I and anti-viral drugs in pre-clinical studies of SARS-CoV-2."],"journal":"Clin Exp Pharmacol Physiol","authors":["Trasino, Steven E"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459003","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/1440-1681.13354","keywords":["covid-19","ifn-i","rig-i","sars-cov-2","interferons","retinoids","vitamin a"],"e_drugs":["Retinoids","Vitamin A"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698839011328,"score":9.490897,"similar":[{"pmid":32403318,"title":"Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","text":["Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs.","Pathogens","Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue","32403318"],"abstract":["Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs."],"journal":"Pathogens","authors":["Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403318","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/pathogens9050367","keywords":["coronavirus","immune evasion","innate immunity","porcine epidemic diarrhea virus","type i ifn"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666802845642391552,"score":346.68683},{"pmid":32464097,"title":"Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","text":["Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.","Cell Host Microbe","Park, Annsea","Iwasaki, Akiko","32464097"],"abstract":["Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19."],"journal":"Cell Host Microbe","authors":["Park, Annsea","Iwasaki, Akiko"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464097","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.chom.2020.05.008","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521320927232,"score":342.3045},{"pmid":32418715,"title":"COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.","text":["COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.","The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs).","Cytokine Growth Factor Rev","Nile, Shivraj Hariram","Nile, Arti","Qiu, Jiayin","Li, Lin","Jia, Xu","Kai, Guoyin","32418715"],"abstract":["The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs)."],"journal":"Cytokine Growth Factor Rev","authors":["Nile, Shivraj Hariram","Nile, Arti","Qiu, Jiayin","Li, Lin","Jia, Xu","Kai, Guoyin"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418715","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cytogfr.2020.05.002","keywords":["covid-19","coronavirus","interferons","recombinant","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896669229056,"score":324.7314},{"pmid":32360182,"title":"Antiviral activities of type I interferons to SARS-CoV-2 infection.","text":["Antiviral activities of type I interferons to SARS-CoV-2 infection.","There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.","Antiviral Res","Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng","32360182"],"abstract":["There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19."],"journal":"Antiviral Res","authors":["Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360182","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.antiviral.2020.104811","keywords":["antiviral therapy","covid-19","innate immune","interferon","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495505137667,"score":317.1061},{"pmid":32407669,"pmcid":"PMC7196896","title":"Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients.","text":["Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients.","The outbreaks of 2019 novel coronavirus disease (COVID-19) caused by SARS-CoV-2 infection have posed a severe threat to global public health. It is unclear how the human immune system responds to this infection. Here, we used metatranscriptomic sequencing to profile immune signatures in the bronchoalveolar lavage fluid of eight COVID-19 cases. The expression of proinflammatory genes, especially chemokines, was markedly elevated in COVID-19 cases compared to community-acquired pneumonia patients and healthy controls, suggesting that SARS-CoV-2 infection causes hypercytokinemia. Compared to SARS-CoV, which is thought to induce inadequate interferon (IFN) responses, SARS-CoV-2 robustly triggered expression of numerous IFN-stimulated genes (ISGs). These ISGs exhibit immunopathogenic potential, with overrepresentation of genes involved in inflammation. The transcriptome data was also used to estimate immune cell populations, revealing increases in activated dendritic cells and neutrophils. Collectively, these host responses to SARS-CoV-2 infection could further our understanding of disease pathogenesis and point toward antiviral strategies.","Cell Host Microbe","Zhou, Zhuo","Ren, Lili","Zhang, Li","Zhong, Jiaxin","Xiao, Yan","Jia, Zhilong","Guo, Li","Yang, Jing","Wang, Chun","Jiang, Shuai","Yang, Donghong","Zhang, Guoliang","Li, Hongru","Chen, Fuhui","Xu, Yu","Chen, Mingwei","Gao, Zhancheng","Yang, Jian","Dong, Jie","Liu, Bo","Zhang, Xiannian","Wang, Weidong","He, Kunlun","Jin, Qi","Li, Mingkun","Wang, Jianwei","32407669"],"abstract":["The outbreaks of 2019 novel coronavirus disease (COVID-19) caused by SARS-CoV-2 infection have posed a severe threat to global public health. It is unclear how the human immune system responds to this infection. Here, we used metatranscriptomic sequencing to profile immune signatures in the bronchoalveolar lavage fluid of eight COVID-19 cases. The expression of proinflammatory genes, especially chemokines, was markedly elevated in COVID-19 cases compared to community-acquired pneumonia patients and healthy controls, suggesting that SARS-CoV-2 infection causes hypercytokinemia. Compared to SARS-CoV, which is thought to induce inadequate interferon (IFN) responses, SARS-CoV-2 robustly triggered expression of numerous IFN-stimulated genes (ISGs). These ISGs exhibit immunopathogenic potential, with overrepresentation of genes involved in inflammation. The transcriptome data was also used to estimate immune cell populations, revealing increases in activated dendritic cells and neutrophils. Collectively, these host responses to SARS-CoV-2 infection could further our understanding of disease pathogenesis and point toward antiviral strategies."],"journal":"Cell Host Microbe","authors":["Zhou, Zhuo","Ren, Lili","Zhang, Li","Zhong, Jiaxin","Xiao, Yan","Jia, Zhilong","Guo, Li","Yang, Jing","Wang, Chun","Jiang, Shuai","Yang, Donghong","Zhang, Guoliang","Li, Hongru","Chen, Fuhui","Xu, Yu","Chen, Mingwei","Gao, Zhancheng","Yang, Jian","Dong, Jie","Liu, Bo","Zhang, Xiannian","Wang, Weidong","He, Kunlun","Jin, Qi","Li, Mingkun","Wang, Jianwei"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407669","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.04.017","keywords":["bronchoalveolar lavage fluid","covid-19","chemokines","coronavirus","hypercytokinemia","innate immune response","interferon response","interferon-stimulated genes","metatranscriptomic sequencing","sars-cov-2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666950579744669696,"score":280.65674}]}